BMI-1 suppresses contact inhibition and stabilizes YAP in Ewing sarcoma

Por Hsu, Jessie H., Lawlor, Elizabeth R.
Publicado em 2010

Outcome-Driven Cluster Analysis with Application to Microarray Data

Por Hsu, Jessie J., Finkelstein, Dianne M., Schoenfeld, David A.
Publicado no PLoS One (2015)

Polycomb repressive complex 2 regulates hematopoietic stem cell maintenance and differentiation in a developmental stage-specific manner

Por Xie, Huafeng, Xu, Jian, Hsu, Jessie H., Nguyen, Minh, Fujiwara, Yuko, Peng, Cong, Orkin, Stuart H.
Publicado em 2013

Modeling Initiation of Ewing Sarcoma in Human Neural Crest Cells

Por von Levetzow, Cornelia, Jiang, Xiaohua, Gwye, Ynnez, von Levetzow, Gregor, Hung, Long, Cooper, Aaron, Hsu, Jessie Hao-Ru, Lawlor, Elizabeth R.
Publicado em 2011

Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Al...

Por Atkins, Michael B., Hsu, Jessie, Lee, Sandra, Cohen, Gary I., Flaherty, Lawrence E., Sosman, Jeffrey A., Sondak, Vernon K., Kirkwood, John M.
Publicado em 2008

BMI-1 promotes Ewing sarcoma tumorigenicity independent of CDKN2A-repression

Por Douglas, Dorothea, Hsu, Jessie Hao-Ru, Hung, Long, Cooper, Aaron, Abdueva, Diana, van Doorninck, John, Peng, Grace, Shimada, Hiro, Triche, Timothy J., Lawlor, Elizabeth R.
Publicado em 2008

Safety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial Program

Por Morley, Roland, Cardenas, Alison, Hawkins, Peter, Suzuki, Yasuyo, Paton, Virginia, Phan, See-Chun, Merchant, Mark, Hsu, Jessie, Yu, Wei, Xia, Qi, Koralek, Daniel, Luhn, Patricia, Aldairy, Wassim
Publicado no PLoS One (2015)

Ewing tumors that do not over-express BMI-1 are a distinct molecular subclass with variant biology: A report from the Children’s Oncology Group

Por Cooper, Aaron, van Doorninck, John, Ji, Lingyun, Russell, Darren, Ladanyi, Marc, Shimada, Hiroyuki, Krailo, Mark, Womer, Richard B., Hsu, Jessie Hao-ru, Thomas, Dafydd, Triche, Timothy J., Sposto, Richard, Lawlor, Elizabeth R.
Publicado em 2010

Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma

Por Green, Adam L., Ramkissoon, Shakti H., McCauley, Dilara, Jones, Kristen, Perry, Jennifer A., Hsu, Jessie Hao-Ru, Ramkissoon, Lori A., Maire, Cecile L., Hubbell-Engler, Benjamin, Knoff, David S., Shacham, Sharon, Ligon, Keith L., Kung, Andrew L.
Publicado no Neuro Oncol (2015)

A Phase II Randomized Trial (GO27827) of First‐Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer

Por Bendell, Johanna C., Hochster, Howard, Hart, Lowell L., Firdaus, Irfan, Mace, Joseph R., McFarlane, Joshua J., Kozloff, Mark, Catenacci, Daniel, Hsu, Jessie J., Hack, Stephen P., Shames, David S., Phan, See‐Chun, Koeppen, Hartmut, Cohn, Allen L.
Publicado no Oncologist (2017)

B-cell Lymphomas with Concurrent IGH-BCL2 and MYC Rearrangements Are Aggressive Neoplasms with Clinical and Pathologic Features Distinct from Burkitt Lymphoma and Diffuse Large B-c...

Por Snuderl, Matija, Kolman, Olga K., Chen, Yi-Bin, Hsu, Jessie J., Ackerman, Adam M., Dal Cin, Paola, Ferry, Judith A., Lee Harris, Nancy, Hasserjian, Robert P., Zukerberg, Lawrence R., Abramson, Jeremy S., Hochberg, Ephraim P., Lee, Hang, Lee, Alfred I., Toomey, Christiana E., Sohani, Aliyah R.
Publicado em 2010